NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

MannKind Corporation (MNKD) Stock Analysis

MannKind Corporation (MNKD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MNKD

$3.05

−$0.05 (−1.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MNKD with… →

MNKD Key Statistics

As of Oct 21, 2026
Trading
Open
$3.10
Previous Close
$3.10
Day's Range
3.04–3.13
52-Week Range
2.23–6.51
Volume
2.80M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.08
Valuation
Market Cap
$980.71M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.59
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
$348.97M+22.23%
Net Income (FY)
$5.86M−78.75%
Profit marginThe share of revenue left as profit after all costs and taxes.
−11.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
321.54M
1-Year Return
−44.65%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
4.49M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MNKD closed at $3.05, −44.65% over 1 year.

MannKind Corporation (MNKD) has a market capitalization of $980.71M.

In fiscal 2025, MNKD reported revenue of $348.97M.

MNKD Stock Return by Calendar Year

MannKind Corporation (MNKD) 10-year return: what $10,000 became

1 year
$10,000 $5,535
−44.65%
5 years
$10,000 $6,916
−30.84%
10 years
$10,000 $10,339
+3.39%

If you had invested $10,000 in MannKind Corporation (MNKD) 10 years ago, at the close on October 21, 2016, it would have been worth $10,339 at the close on October 21, 2026: +3.39% in total, +0.33% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.21%
2025−11.82%
2024+76.65%
2023−30.93%
2022+20.59%
2021+39.62%
2020+142.64%
2019+21.70%
2018−54.31%
2017−27.50%
2016 (partial year)−36.00%

As of October 21, 2026.

MNKD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$348.97M$5.86M1.7%
2024$285.50M$27.59M9.7%
2023$198.96M−$11.94M−6.0%
2022$99.77M−$87.40M−87.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$348.97M$261.01M$46.55M$5.86M1.7%
2024$285.50M$208.90M$68.68M$27.59M9.7%
2023$198.96M$136.19M$10.59M−$11.94M−6.0%
2022$99.77M$42.27M−$68.92M−$87.40M−87.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MNKD Valuation vs Biotechnology Median

Median of 608 stocks
MetricMNKDBiotechnology medianvs median
P/S ratio2.4913.300.2x the median
Profit margin−11.08%−38.31%27.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MannKind Corporation (MNKD) is capitalised at $980.71M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 591.

Over the past 52 weeks the price has ranged from $2.23 to $6.51. MNKD last closed at $3.05 on October 21, 2026. That is −$0.05 (−1.61%) against the previous close. The latest close sits 36.77% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $348.97M. Against the prior fiscal year total of $285.50M, that is a change of +22.23%. The same year closed with net income of $5.86M. That is −78.75% against the prior fiscal year. The reported profit margin is −11.08%. That is 27.2 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −0.14.

Across the 4 fiscal years on file, revenue moves from $99.77M in 2022 to $348.97M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 22.59. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.39. The price-to-sales ratio is 2.49. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.08. Daily returns over the trailing 10 years annualize to a volatility of 82.68%. The trailing one-year total return is −44.65%. Measured over 10 years, that is +0.33% a year compounded.

Growth & Income

No dividend is on file for MNKD.

2026 is still running; the total return is −46.21% year to date. The strongest complete calendar year on file is 2020 at +142.64%; the weakest is 2018 at −54.31%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

MannKind Corporation (MNKD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MannKind Corporation MNKD $980.71M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. MannKind Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Visit website →